Immune Function of Infants with HIV

This observational study will evaluate data from infants born to HIV infected mothers in order to better characterize disease progression in early HIV infection.

Official Title

Killer Cells and Viral Load in Vertical HIV Infection

Conditions

HIV Infections

Study Type

Observational

Study Design

Natural History, Longitudinal, Defined Population, Retrospective/Prospective Study

Further Details

The role of HIV-specific cytotoxic T-lymphocytes (CTL) in controlling viremia and protecting against disease progression following vertical infection may be dependent upon CTL functional responses as well as on the timing of detection, magnitude, and breadth of the responses. Novel and sensitive assay systems (MHC-peptide tetramers, ELISPOT assays, intracellular cytokine assays) have enhanced the detection and characterization of virus-specific CTL responses in the peripheral blood. This study will use these novel methods to examine the timing of detection, magnitude, specificity, and in vitro functional properties of HIV-specific CTL in infants; to evaluate the effects of potent combination antiretroviral therapy on HIV-specific CTL in infants; and to evaluate the immunogenicity of recombinant pox-based vaccines in HIV infected infants with prolonged viral suppression following early potent combination antiretroviral therapy. Blood samples from infants born to HIV infected women will be obtained from infants enrolled in other HIV trials. Generally, samples will be obtained at birth, Week 1, and Months 1, 2, 4, 6, 9, and 12.

Study Start

Eligibility & Criteria

Ages Eligible for Study: up to 24 Months, Genders Eligible for Study: Both Criteria Inclusion Criteria:Infants and children born to HIV infected women

Total Enrolment

80

Contact Details

[1] Katherine Luzuriaga, MD, Principal Investigator, University of Massachusetts [2] National Institute of Allergy and Infectious Diseases (NIAID) (US)